Real-life experience of tildrakizumab 200 mg in complex psoriatic patients: a case series.

BACKGROUND/

OBJECTIVES

The management of moderate-to-severe plaque psoriasis may be particularly challenging in patients with a high disease burden and multiple comorbidities. This case series provides real-world evidence on the effectiveness of tildrakizumab 200 mg in patients with moderate-to-severe psoriasis characterized by clinical factors such as multiple comorbidities, high body weight, involvement of difficult-to-treat areas, and prior therapeutic failures.

METHODS

We present a series of six clinical cases describing baseline characteristics, treatment history and outcomes of patients with moderate-to-severe psoriasis treated with tildrakizumab 200 mg.

RESULTS

Although most of the patients included in this report showed multiple chronic or acute comorbidities (mainly cardiometabolic), high body weight, involvement of difficult-to-treat areas and failure to previous treatments (including biologics), tildrakizumab induced mostly complete remissions with most patients achieving PASI90 or PASI100 responses within 4-12 weeks; complete clearance (PASI100) was observed in four out of six patients. Treatment effectiveness was maintained over a follow-up of approximately 24 months in most cases, with a favorable safety profile.

CONCLUSIONS

Tildrakizumab 200 mg demonstrated high effectiveness and sustained clinical responses in patients with moderate-to-severe psoriasis characterized by high disease burden and multiple comorbidities in a real-world setting.